CDK4 and breast carcinoma: Furthermore, in a study of ER+ breast cancer, Pingping Shen et al. [82] reported that MCF-7 breast cancer cell lines treated with CDK4/6 inhibitors generally experience senescence and subsequently exhibit increased expression of stemness-related genes.